{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:25:33Z","timestamp":1789133133184,"version":"build-2803163510"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"F2G, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>All triazoles decrease the metabolism of calcineurin inhibitors (CNIs) and mammalian target of rapamycin (mTOR) inhibitors through CYP3A4 and P-glycoprotein inhibition leading to increased exposure and the potential for serious adverse events (SAEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We sought to describe triazoles and CNI and mTOR inhibitor use in solid organ transplantation (SOT) recipients hospitalized for invasive aspergillosis (IA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>We included adults with \u22651 claim for an IA admission in a US claims database from October 2015 to November 2022 who received systemic antifungal therapy for \u22653\u2005days during the stay. This cohort was limited to patients with a history of SOT (defined as \u22651 diagnosis code for post-transplant status and\/or complication) between January 2010 and IA admission. Triazoles and CNI or mTOR inhibitor co-administration in newly admitted IA patients were described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 173 admitted IA patients with SOT. Kidney and lung transplant were most prevalent (&amp;gt;42% for both). Triazoles were used in 170 (98.3%) of patients (mean duration, \u200a116\u200a\u00b1\u200a184 post-admission days). Voriconazole (71.1%) and isavuconazole (41.0%) were most prescribed, and triazoles were co-administered with a CNI or mTOR inhibitor in 139 (81.8%) of patients. Tacrolimus was the predominantly used (89.9%) immunosuppressant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Voriconazole was used nearly twice as frequently as isavuconazole, despite isavuconazole having more predictable pharmacokinetics and a lower propensity for severe drug\u2013drug interactions versus voriconazole. The still-frequent use of isavuconazole may reflect its lower inhibition of CNIs and mTOR inhibitors. Resulting drug\u2013drug interactions may be serious and dose adjustment and therapeutic drug monitoring are needed to reduce SAEs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf461","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T13:21:10Z","timestamp":1764768070000},"source":"Crossref","is-referenced-by-count":2,"title":["Co-administration of triazoles with calcineurin or mammalian target of rapamycin inhibitors in solid organ transplant patients hospitalized with invasive aspergillosis"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5868-0529","authenticated-orcid":false,"given":"Barbara","family":"Alexander","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases & International Health, Duke University , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6606-9460","authenticated-orcid":false,"given":"Melissa D","family":"Johnson","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases & International Health, Duke University , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda","family":"Lovelace","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, F2G Inc. , Princeton, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4868-7158","authenticated-orcid":false,"given":"Craig I","family":"Coleman","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Connecticut , 69 North Eagleville Road, Unit 3092, Storrs, CT 06269-3092 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"2026011413263324600_dkaf461-B1","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1056\/NEJMra2027424","article-title":"Aspergillus infections","volume":"385","author":"Thompson","year":"2021","journal-title":"N Engl J Med"},{"key":"2026011413263324600_dkaf461-B2","doi-asserted-by":"publisher","first-page":"e12898","DOI":"10.1111\/tid.12898","article-title":"Epidemiology, risk factors and outcomes of invasive aspergillosis in solid organ transplant recipients in the Swiss Transplant Cohort Study","volume":"20","author":"Neofytos","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"2026011413263324600_dkaf461-B3","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1097\/TXD.0000000000000584","article-title":"Prognosis of invasive aspergillosis in kidney transplant recipients: a case\u2013control study","volume":"2","author":"Desbois","year":"2016","journal-title":"Transplant Direct"},{"key":"2026011413263324600_dkaf461-B4","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3390\/jof11090657","article-title":"Healthcare resource utilization, treatment costs, and mortality in patients with malignancies or transplantation who develop invasive aspergillosis","volume":"11","author":"Walsh","year":"2025","journal-title":"J Fungi"},{"key":"2026011413263324600_dkaf461-B5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/phar.2716","article-title":"Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: Endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and the International Society for Heart and Lung Transplantation","volume":"42","author":"Nelson","year":"2022","journal-title":"Pharmacotherapy"},{"key":"2026011413263324600_dkaf461-B6","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026011413263324600_dkaf461-B7","doi-asserted-by":"publisher","first-page":"e13544","DOI":"10.1111\/ctr.13544","article-title":"Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Husain","year":"2019","journal-title":"Clin Transplant"},{"key":"2026011413263324600_dkaf461-B8","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/jac\/dkae103","article-title":"Triazole antifungal drug interactions-practical considerations for excellent prescribing","volume":"79","author":"Lewis","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026011413263324600_dkaf461-B9","author":"National Aspergillosis Center"},{"key":"2026011413263324600_dkaf461-B10","author":"IQVIA"},{"key":"2026011413263324600_dkaf461-B11","doi-asserted-by":"publisher","first-page":"e00585-18","DOI":"10.1128\/AAC.00585-18","article-title":"Isavuconazole concentration in real-world practice: consistency with results from clinical trials","volume":"62","author":"Andes","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413263324600_dkaf461-B12","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1128\/AAC.00054-16","article-title":"Drug-drug interaction associated with mold-active triazoles among hospitalized patients","volume":"60","author":"Andes","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413263324600_dkaf461-B13","doi-asserted-by":"publisher","first-page":"236","DOI":"10.37201\/req\/013.2023","article-title":"Recommendations on the use of azole antifungals in hematology-oncology patients","volume":"36","author":"Azanza","year":"2023","journal-title":"Rev Esp Quimioter"},{"key":"2026011413263324600_dkaf461-B14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.18553\/jmcp.1999.5.3.215","article-title":"Administrative databases and outcomes assessment: an overview of issues and potential utility","volume":"5","author":"Gandhi","year":"1999","journal-title":"J Manag Care Pharm"},{"key":"2026011413263324600_dkaf461-B15","doi-asserted-by":"publisher","first-page":"106568","DOI":"10.1016\/j.jinf.2025.106568","article-title":"Geographic distribution and associated mortality of invasive aspergillosis and mucormycosis among Medicare enrollees in the United States (2008\u20132015)","volume":"91","author":"Zuniga-Moya","year":"2025","journal-title":"J Infect"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf461\/66031352\/dkaf461.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf461\/66031352\/dkaf461.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:26:36Z","timestamp":1768415196000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf461\/8384097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf461","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,12,19]]},"article-number":"dkaf461"}}